DuPont Merck Pharmaceuticals
Executive Summary
Drops interleukin-1 therapeutic research under a renegotiated agreement with Cistron, the company announced Aug. 7. DuPont had licensed IL-1 from Cistron in 1985, and the license was assigned to DuPont Merck when that company was formed last year. Under the new agreement, DuPont will have rights to IL-1 for the research market, and Cistron will be free to seek new partners for IL-1 therapeutics.